Circulating Epithelial Tumor Cells (CETC/CTC) in Prostate Cancer: Potential Prognostic Marker for the Risk of Recurrence During Radiotherapy
International Journal of Molecular Sciences · 12.02.2025 · 26 (4) · 1548
DOI: 10.3390/ijms26041548 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.02.2025. Verfasst von Dorothea Schott und 6 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion Medicine Center Bayreuth, Kurpromenade 2, 95448 Bayreuth, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplastic Cells, Circulating, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Interdisciplinary Center of Clinical Research of the Medical Faculty Jena, Else-Kroner-Fresenius-Stiftung.
Abstract (Originalsprache)
Prostate cancer is a leading cause of cancer-related mortality in men, with radiotherapy (RT) playing a pivotal role in treatment. However, reliable biomarkers for assessing relapse risk following RT remain scarce. This study aimed to evaluate circulating epithelial tumor cells (CETC/CTC) as potential biomarkers for assessing relapse risk in prostate cancer patients undergoing RT. Peripheral blood samples were collected from 52 prostate cancer patients, and CETC/CTC were detected using the EpCAM surface marker. Patients received definitive, adjuvant, or salvage RT, and CETC/CTC counts were measured before, at mid-treatment, and at the end of RT. The association between changes in CETC/CTC counts and relapse risk was examined. CETC/CTC were detected in 96% of patients prior to RT. A significant reduction in CETC/CTC counts during RT, particularly in patients who had undergone surgery, was associated with a lower relapse risk. In contrast, an increase in CETC/CTC counts during or after RT was associated with a higher relapse risk (hazard ratio = 8.8; p = 0.002). Furthermore, 36% of patients receiving adjuvant RT and 14% of those receiving definitive RT relapsed, with a higher risk observed in patients showing increasing CETC/CTC counts during RT. Among patients receiving salvage RT, 18% relapsed, though changes in CETC/CTC counts were less significantly associated with relapse. Monitoring CETC/CTC levels during RT offers important prognostic insights into relapse risk in prostate cancer patients. While changes in CETC/CTC counts correlated with relapse, PSA levels measured during the study did not reliably reflect relapse risk in this cohort. CETC/CTC shows promise as a prognostic marker, though further studies are required to validate its clinical superiority over PSA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transfusion Medicine Center Bayreuth, Kurpromenade 2, 95448 Bayreuth, Germany.
- Department of Radiotherapy and Radiation Oncology, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.
- Department of Neurology, Neurooncology Center, University Hospital, Am Klinikum 1, 07747 Jena, Germany.
- Clinician Scientist Program, Interdisciplinary Center for Clinical Research (IZKF), Jena Hospital, 07747 Jena, Germany.
- Clinician Scientist Program OrganAge, Interdisciplinary Center for Clinical Research (IZKF), Jena Hospital, 07747 Jena, Germany.
ORCID-Profile: Monika Pizon, Georg Wurschi, Matthias Mäurer
Förderung
- Deutsche Forschungsgemeinschaft
- Interdisciplinary Center of Clinical Research of the Medical Faculty Jena
- Else-Kroner-Fresenius-Stiftung
Zitieren
APA
Schott, D., Pizon, M., Drozdz, S., Mäurer, I., Wurschi, G., Pachmann, K., & Mäurer, M. (2025). Circulating Epithelial Tumor Cells (CETC/CTC) in Prostate Cancer: Potential Prognostic Marker for the Risk of Recurrence During Radiotherapy. International Journal of Molecular Sciences, 26(4), 1548. https://doi.org/10.3390/ijms26041548
Vancouver
Schott D, Pizon M, Drozdz S, Mäurer I, Wurschi G, Pachmann K, et al. Circulating Epithelial Tumor Cells (CETC/CTC) in Prostate Cancer: Potential Prognostic Marker for the Risk of Recurrence During Radiotherapy. International Journal of Molecular Sciences. 2025;26(4):1548. doi:10.3390/ijms26041548
BibTeX
@article{Schott2025,
author = {Schott, Dorothea and Pizon, Monika and Drozdz, Sonia and Mäurer, Irina and Wurschi, Georg and Pachmann, Katharina and Mäurer, Matthias},
title = {Circulating Epithelial Tumor Cells (CETC/CTC) in Prostate Cancer: Potential Prognostic Marker for the Risk of Recurrence During Radiotherapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {4},
pages = {1548},
doi = {10.3390/ijms26041548}
}
EUVIMED